Motavizumab Advisory Committee To Consider Possible Study Bias
Concerns FDA raised in its "complete response" letter to MedImmune for its monoclonal antibody Rezield (motavizumab) have not been addressed to the agency's complete satisfaction.
Concerns FDA raised in its "complete response" letter to MedImmune for its monoclonal antibody Rezield (motavizumab) have not been addressed to the agency's complete satisfaction.